MarketPulse

T-cell engagers

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··World Street Intelligence News Commentary

Cold Tumors Heat Up: New Immunotherapy Wave Targets Resistant Cancers

Novel immune-priming therapies targeting treatment-resistant solid tumors advance through trials in 2026, with $1.7B in dealmaking across four mechanistic approaches.
VIRSNSEONCYGTBPclinical trialssolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Oxford Biotherapeutics

Oxford BioTherapeutics Lands Major Deal with Bristol Myers Squibb on Cancer Immunotherapy

Oxford BioTherapeutics partners with Bristol Myers Squibb to develop T-cell engager therapies for solid tumors, marking third major pharma deal in a year.
BMYCELGroncologyAntibody-Drug Conjugates